EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival

Adriana Gutiérrez-Hoya, Ivan Ortiz-Garrido, Itzel Salazar-Valencia, Christopher Romero-Hernández iD, Arturo Valle-Mendiola iD, Benny Weiss-Steider iD, Isabel Soto-Cruz iD

Biomolecules · 2024

DOI: 10.3390/biom14121543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Adriana Gutiérrez-Hoya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, UMIEZ Campus II FES Zaragoza, National Autonomous University of Mexico,…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Cell Proliferation, fas Receptor, Interleukin-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Nacional Autónoma de México, Dirección General de Asuntos del Personal Académico (DGAPA), Universidad Nacional Autónoma de México (UNAM).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer is a global health problem; therapies focused on eliminating tumour cells and strengthening different immunotherapies are in development. However, it has been observed that cervical tumour cells can evade cell death mechanisms and generate immune system molecules to promote their proliferation and metastasis. In this context, we analysed the role of the IL-2 and CD95 pathways, essential molecules in activating the immune system and eliminating tumour cells. However, it is important to analyse their role in cervical tumour cells because these cells could be using these pathways to proliferate. In this study, we found that SiHa and HeLa cells respond to treatment, with 10 IU/mL of IL-2 inducing their proliferation and 100 IU/mL of IL-2 decreasing their proliferation. We also observed that they express a high percentage of the CD95 receptor and its ligand (CD95L) and that treatment with CD95 agonist antibodies at low doses increases cell proliferation. Furthermore, simultaneous treatment with high doses of IL-2 plus CD95 agonist antibody positively regulates LC3B accumulation. We did not observe apoptosis under any of the treatments carried out. In conclusion, cervical tumour cells can use the IL-2 and CD95 pathways to induce their proliferation and potentially activate cytoprotective mechanisms for survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsCell Proliferationfas ReceptorInterleukin-2Cell SurvivalHumansFemaleHeLa CellsSignal TransductionFas Ligand ProteinApoptosisCell Line, Tumor

Stichwörter der Autor:innen

CD95LC3B fociagonist antibodiescell proliferationcervical cancerinterleukin-2

Substanzen

fas ReceptorInterleukin-2FAS protein, humanFas Ligand Protein

Autor:innen und Institutionen

  • Molecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, UMIEZ Campus II FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.
  • Researcher CONAHCYT, Consejo Nacional de Humanidades, Ciencias y Tecnologías, Col. Crédito Constructor, Benito Juárez, Mexico City 03940, Mexico.
  • Population Genomics Unit Applied to Health, Faculty of Chemistry, National Autonomous University of Mexico, Mexico City 14610, Mexico.
  • Postgraduate Program in Biological Sciences, Postgraduate Unit, Building D, 1st Floor, University City, National Autonomous University of Mexico, Coyoacán, Mexico City 04510, Mexico.

ORCID-Profile: Christopher Romero-Hernández, Arturo Valle-Mendiola, Benny Weiss-Steider, Isabel Soto-Cruz

Förderung

  • Universidad Nacional Autónoma de México
  • Dirección General de Asuntos del Personal Académico (DGAPA), Universidad Nacional Autónoma de México (UNAM)

Zitieren

APA

Gutiérrez-Hoya, A., Ortiz-Garrido, I., Salazar-Valencia, I., Romero-Hernández, C., Valle-Mendiola, A., Weiss-Steider, B., & Soto-Cruz, I. (2024). Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival. Biomolecules. https://doi.org/10.3390/biom14121543

Vancouver

Gutiérrez-Hoya A, Ortiz-Garrido I, Salazar-Valencia I, Romero-Hernández C, Valle-Mendiola A, Weiss-Steider B, et al. Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival. Biomolecules. 2024. doi:10.3390/biom14121543

BibTeX
@article{GutirrezHoya2024,
  author = {Gutiérrez-Hoya, Adriana and Ortiz-Garrido, Ivan and Salazar-Valencia, Itzel and Romero-Hernández, Christopher and Valle-Mendiola, Arturo and Weiss-Steider, Benny and Soto-Cruz, Isabel},
  title = {Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14121543}
}
Kostenlos starten →